[1] Vassilev T,Bauer M.Passive immunotherapy of Sepsis with intravenous immune globulin:not all IVIg preparations are created equal[J].Crit Care,2012,16(1):1. [2] Mair-Jenkins J,Saavedra-Campos M,Baillie J K,et al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology:a systematic review and exploratory meta-analysis[J].J Infect Dis,2015,211(1):80-90. [3] 杨晓明,侯继峰.康复期血浆应用于急性病毒性传染病现状及其治疗新型冠状病毒肺炎前景[J].中国生物制品学杂志,2020,33(3):241-245. [4] Marano G,Vaglio S,Pupella S,et al.Convalescent plasma:new evidence for an old therapeutic tool?[J].Blood Transfus,2016,14(2):152-157. [5] Wong V W S,Dai D,Wu A K L,et al.Treatment of severe acute respiratory syndrome with convalescent plasma[J].Hong Kong Med J,2003,9(3):199-201. [6] Garraud O.Use of convalescent plasma in Ebola virus infection[J].Transfus Apher Sci,2017,56(1):31-34. [7] Hung I F,To K K,Lee C K,et al.Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection[J].Clin Infect Dis,2011,52(4):447-456. [8] Emerging understandingsof 2019-nCoV[J].Lancet,2020,395(10221):311. [9] van Griensven J,Edwards T,de Lamballerie X,et al.Evaluation of convalescent plasma for Ebola virus disease in Guinea[J].N Engl J Med,2016,374(1):33-42. [10] Tanaka T,Narazaki M,Kishimoto T.IL-6 in inflammation,immunity,and disease[J].Cold Spring Harb Perspect Biol,2014,6(10):a016295. [11] Chen L,Liu H G,Liu W,et al.Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia[J].Zhonghua Jie Hu Xi Za Zhi,2020,43(0):E005. [12] 季明霞,斯小水,何建新,等.NT-proBNP、TNF-α 、IL-6在急性呼吸窘迫综合征严重程度及预后评估中的应用价值[J].浙江医学,2016,38(22):1808-1810. [13] 刘映霞,杨扬,张聪,等.新型冠状病毒(2019-nCoV)感染患者肺损伤相关的临床及生化指标研究[J].中国科学(生命科学),2020,50(3):258-269. |